---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-26-000024"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:58:10.582713+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akebia appoints Philip Vickers to board, replacing retiring Steven Gilman

## Summary
- Steven Gilman resigned as Class I director effective April 1, 2026; retirement not due to any disagreement.
- Philip Vickers elected Class I director effective April 1, 2026; term expires at 2027 annual meeting.
- Vickers appointed to Compensation and R&D Committees; receives standard non-employee director compensation.
- Vickers granted 214,400 options at $1.41/share on April 1, plus annual cash retainers of $50,000.
- Vickers is CEO of Solu Therapeutics; over 30 years biopharma leadership including Shire and Pfizer.

## SEC filing metadata
- accession: 0001517022-26-000024
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000024/0001517022-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000024/akba-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-26-000024
- JSON: https://secwatch.observer/filing/0001517022-26-000024.json
- Plain text: https://secwatch.observer/filing/0001517022-26-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.